Candesartan in the prevention of cardiovascular catastrophes: emphasis on the pre-vention of stroke

Full Text


Arterial hypertension is one of the most important risk factors of acute cerebral circulatory disorders. Many clinical studies indicate that there are mechanisms that permit the prevention of stroke irrespective of a direct reduction in blood pressure. Antihypertensive agents affecting the renin-angiotensin-aldosterone system may have a cerebral protective effect beyond blood pres-sure lowering. The ability of angiotensin II receptor antagonists to prevent the development of stroke is associated with the fact that with the use of these agents, angiotensin II interacts with AT2-receptors, thereby improving the blood flow in the brain and enhancing the neuronal resis-tance to hypoxia. In this review, the focus is on the capacity of the angiotensin II receptor an-tagonist candesartan to prevent severe cerebrovascular events.


  1. WHO atlas of heart disease and stroke. 15_burden_stroke.pdf. Accessed July 8, 2009.
  2. Meairs S, Wahlgren N, Dirnagl U et al. Stroke research priorities for the next decade - a representative view of the European scientific community. Cerebrovasc Dis 2006; 22 (2-3): 75-82.
  3. Драпкина О.М., Ашихмин Я.И., Ивашкин В.Т. Профилактика инсульта. Рос. мед. вести. 2007; 4: 60-75.
  4. Neal B, MacMahon S. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-41.
  5. Flather MD, Yusuf S, Kober L et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000; 355 (9215): 1575-81.
  6. Boutitie F, Oprisiu R, Achard JM et al. Does a change in angiotensin II formation caused by antihypertensive drugs affect the risk of stroke? A meta-analysis of trials according to treatment with potentially different effects on angiotensin II. J Hypertens 2007; 25 (8): 1543-53.
  7. Kozak A, Ergul A, El-Remessy AB et al. Candesartan Augments Ischemia-Induced Proangiogenic State and Results in Sustained Improvement After Stroke. Stroke 2009; 40: 1870-6.
  8. Warner KK, Visconti JA, Tschampel MM. Angiotensin II receptor blockers in patients with ACE inhibitor-induced angioedema. Ann Pharmacother 2000; 34: 526.
  9. Драпкина О.М., Дикур О.Н. Преимущество антагонистов рецепторов ангиотензина II в лечении АГ у женщин. Рус. мед. журн. 2008; 16 (21): 1462-5.
  10. Granger CB, McMurray JJ, Yusuf S et al. Effects of candesartan in patients with chronic heart failure and reduced left. ventricular systolic function intolerant to angiotensin.converting.enzyme inhibitors: the CHARM. Alternative trial. Lancet 2003; 362: 772-6.
  11. Мареев В.Ю., Агеев Ф.Т. и др. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (2-й пересмотр). Сердечн. недостат. 2006; 8 (2).
  12. Yusuf S, Pfeffer MA, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and preserved left. ventricular ejection fraction: the CHARM Preserved Trial. Lancet 2003; 362: 777-81.
  13. Lindholm LH, Persson M, Alaupovic P et al. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 2003; 21: 1563-74.
  14. Cuspidi C, Muiesan ML, Valagussa L et al. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. J Hypertens 2002; 20: 2293-300.
  15. Grassi G, Seravalle G, Dell'Oro R et al. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens 2003; 21: 1761-9.
  16. Lithell H, Hansson L, Skoog I et al. The Study on Cognition and Prognosis in the Eldery (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875-86.
  17. Schrader J, Luders S, Kollmann K et al. The ACCESS Study. Evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 2003; 34: 1699-703.
  18. Neyer J et al. A report from the American Heart Association Statistics Commettee and Stroke Statistics Subcommettee. Circulation 2007; 115: e69-171.
  19. Kasanuki H. et al European Heart Journal (2009)30, 1203-12.



Abstract: 138


Article Metrics

Metrics Loading ...



  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies